Patients with SARD-ILD-PPF who continued nintedanib for 12 months or longer had better outcomes than those who discontinued therapy.

More people than ever are entering medical school, and with the number of applicants increasing, it is harder to get in.

Novo Nordisk announced the availability of Wegovy tablets, the first oral GLP-1 receptor agonist for weight loss and CV risk reduction.

Elexacaftor/tezacaftor/ivacaftor use is linked to long-term decreases in chronic respiratory therapies in patients with cystic fibrosis.

Individuals with a history of immune-mediated inflammatory diseases (IMIDs) may have a higher risk for sarcoidosis onset, a Japanese study found.

A pulmonologist is sued after responding to a call from ICU staff to prevent airway collapse in a patient who was ultimately left disabled.

For the fifth consecutive year, the number of American teenagers using drugs and alcohol remains at a historic low.

Abortion will stay legal in Wyoming after the state Supreme Court ruled that abortion bans passed by lawmakers violate the state constitution.

Researchers sought to determine the longer-term effects of intensive blood pressure control in older patients.

Researchers evaluated whether pregnancy complications, early childhood characteristics, and tobacco-related exposures were associated with SARDs.

The FDA has granted Breakthrough Therapy designation to alixorexton for the treatment of narcolepsy type 1 (NT1).

Penicillin allergy de-labeling occurs less in patients who are Black and Asian vs White, with prevalence rates varying among health systems.